Shots:

• AstraZeneca will evaluate the combination of Monalizumab with Cetuximab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with the anticipated onset of the study in 2020
• In Apr’2015- AstraZeneca and Innate collaborated to co-develop & co-commercialize Monalizumab for $1.275B out of which Innate has received $350M and will receive $100M upon dosing of the first patient in P-III study along with royalties on sales (Ex-EU). Innate will equally share profit & loss in the territory and will co-fund 30% development cost in P-III study
• In Oct’2018- AstraZeneca acquired full rights of Monalizumab from Innate. Monalizumab is an immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells and NK cells while Cetuximab is an anti-EGFR mAb

Click here to­ read full press release/ article 

Ref: Businesswire | Image: AstraZeneca